Momelotinib: Risk of Decreased Platelet and White Blood Cell Counts

Release date: 2026-06-22 16:23:39     Recommended: 14

Momelotinib: Risk of Decreased Platelet and White Blood Cell Counts

Momelotinib may cause or worsen decreases in platelet and white blood cell counts. Thrombocytopenia increases bleeding tendency, manifesting as skin bruising, gum bleeding, epistaxis, or internal bleeding; leukopenia weakens immune defense and further raises the risk of infection. To dynamically track blood count changes, physicians will arrange regular blood tests before and during treatment, typically including a complete blood count. If platelet or neutrophil counts drop to dangerous levels, the doctor may take measures such as dose adjustment, temporary interruption, or permanent discontinuation. During treatment, patients must immediately inform the medical team if they notice any signs of abnormal bleeding (e.g., unexplained bruising, black or tarry stools). Meanwhile, in daily activities, patients should avoid bumps, use a soft-bristled toothbrush, and exercise caution with invasive procedures to reduce bleeding risk. Regular monitoring is a key element in ensuring medication safety.

Momelotinib: Liver-Related Side Effects and Monitoring Requirements

Elevated liver enzymes and increased bilirubin are potential hepatic adverse reactions of momelotinib. These abnormalities may indicate hepatocellular injury or cholestasis, and in severe cases can affect liver function. For this reason, baseline liver enzyme levels must be measured before treatment, and during the first 6 months of therapy, tests should be repeated monthly, with subsequent frequency adjusted based on clinical need. If liver enzymes rise significantly, the doctor may interrupt momelotinib until recovery or permanently discontinue treatment. Patients should be alert to the following warning signs of liver problems: persistent fatigue, loss of appetite, right upper quadrant pain, dark urine, or yellowing of the skin or sclera. Should any of these manifestations occur, do not delay—contact your doctor immediately for further evaluation. Patients with coexisting liver diseases (e.g., fatty liver, viral hepatitis) should inform their medical history in advance so that a more tailored monitoring plan can be developed, ensuring that liver safety is maximally protected while controlling myelofibrosis.

Momelotinib: Possibility of Severe Skin Reactions

Although rare, momelotinib may induce life-threatening severe skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. These reactions typically present with a progressive rash as an early sign, with or without fever. Other warning symptoms include severe rash, widespread skin redness, flu-like prodromal symptoms, skin pain or burning sensation, and blistering of the lips, eyes, or oral mucosa, as well as skin peeling. If any of these signs occur, patients must immediately stop momelotinib and seek emergency medical care, without waiting for the rash to resolve on its own. Early recognition and prompt management are critical to prognosis. To reduce risk, patients should closely observe skin changes during the early phase of treatment, especially within the first few weeks. If there is a history of drug allergy or severe skin reactions, this should be proactively disclosed to the physician before starting therapy, so that individual risk can be assessed and preventive strategies can be devised.